Everest Medicines' issued shares increase after equity plan exercises

Everest Medicines Limited announced an increase in its total issued shares, rising from 350,928,043 on August 31, 2025, to 353,535,381 as of September 5, 2025. This change is primarily due to two events occurring on September 2, 2025, and September 5, 2025.

The first event, dated September 2, 2025, involved the issue of 1,257 new shares at a price of HK$23.17 per share. These shares were issued in respect of share awards or options granted to participants under a share scheme and pursuant to the exercise of share options granted under the Post-IPO Share Option Scheme. This represented 0.0004% of the existing number of issued shares before the event.

The second, more substantial, change occurred on September 5, 2025, with the issue of 2,606,081 new shares. These shares were issued pursuant to the Pre-IPO employee equity plan and the Post-IPO share award scheme. This issuance constituted 0.7426% of the company's issued shares prior to the event, contributing significantly to the overall increase in Everest Medicines' total issued shares.